{"organizations": [], "uuid": "f3e3e88359004707a2967adeefdc116a550131b6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shenyang-xingqi-pharmaceutical-see/brief-shenyang-xingqi-pharmaceutical-sees-fy-2017-net-profit-to-down-20-8-pct-to-28-4-pct-idUSL4N1PK2CX", "country": "US", "domain_rank": 408, "title": "BRIEF-Shenyang Xingqi Pharmaceutical sees FY 2017 net profit to down 20.8 pct to 28.4 pct", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.334, "site_type": "news", "published": "2018-01-25T14:11:00.000+02:00", "replies_count": 0, "uuid": "f3e3e88359004707a2967adeefdc116a550131b6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shenyang-xingqi-pharmaceutical-see/brief-shenyang-xingqi-pharmaceutical-sees-fy-2017-net-profit-to-down-20-8-pct-to-28-4-pct-idUSL4N1PK2CX", "ord_in_thread": 0, "title": "BRIEF-Shenyang Xingqi Pharmaceutical sees FY 2017 net profit to down 20.8 pct to 28.4 pct", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "shenyang xingqi pharmaceutical co ltd", "sentiment": "negative"}, {"name": "brief-shenyang xingqi pharmaceutical", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - Shenyang Xingqi Pharmaceutical Co Ltd :\n* Sees net profit for FY 2017 to decrease by 20.8 percent to 28.4 percent, compared to net profit of FY 2016 (54.3 million yuan)\n* Says decreased combined gross profit rate and increased R&D cost as main reasons for the forecast\nSource text in Chinese: goo.gl/sSpMd9\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/sSpMd9", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T14:11:00.000+02:00", "crawled": "2018-01-26T21:30:26.000+02:00", "highlightTitle": ""}